These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 16731288

  • 1. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
    Basi S, Lewis JB.
    Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
    [Abstract] [Full Text] [Related]

  • 2. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D.
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [Abstract] [Full Text] [Related]

  • 3. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A, Bashir K, Anwar E.
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [Abstract] [Full Text] [Related]

  • 4. [Microalbuminuria in diabetes: setting the points for treatment].
    Lehnert H, Klose S, Lobmann R, Zehnder D.
    MMW Fortschr Med; 2006 May 25; 148(21):28-30, 33; quiz 34. PubMed ID: 16796185
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov 25; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 6. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B, Berland Y.
    Nephrol Ther; 2006 May 25; 2(2):51-74. PubMed ID: 16895717
    [Abstract] [Full Text] [Related]

  • 7. Microalbuminuria, insulin resistance, diabetes, hypertension, and kidney function: the latest concepts in pathology and pharmacologic treatment.
    Barri YM, Palmer BF, Ram CV.
    Postgrad Med; 2005 Dec 25; 118(6 Suppl Beta-Blockers):34-45. PubMed ID: 19667709
    [Abstract] [Full Text] [Related]

  • 8. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB.
    Postgrad Med; 2009 Mar 25; 121(2):89-101. PubMed ID: 19332966
    [Abstract] [Full Text] [Related]

  • 9. Management of hypertension in patients with chronic kidney disease and diabetes mellitus.
    Palmer BF.
    Am J Med; 2008 Aug 25; 121(8 Suppl):S16-22. PubMed ID: 18638614
    [Abstract] [Full Text] [Related]

  • 10. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
    Remuzzi G, Macia M, Ruggenenti P.
    J Am Soc Nephrol; 2006 Apr 25; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
    [Abstract] [Full Text] [Related]

  • 11. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H, O'Keefe J.
    Diabetes Obes Metab; 2008 Dec 25; 10(12):1157-66. PubMed ID: 18494810
    [Abstract] [Full Text] [Related]

  • 12. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO, Coll JR, Tran ZV, Schrier RW.
    Am J Hypertens; 2006 Dec 25; 19(12):1241-8. PubMed ID: 17161769
    [Abstract] [Full Text] [Related]

  • 13. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
    Esnault V.
    Nephrol Ther; 2006 May 25; 2 Suppl 3():S193-6. PubMed ID: 17370850
    [Abstract] [Full Text] [Related]

  • 14. Preserving the diabetic kidney.
    Poirier SJ.
    J Fam Pract; 1998 Jan 25; 46(1):21-7. PubMed ID: 9451365
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
    Maione A, Nicolucci A, Craig JC, Tognoni G, Moschetta A, Palasciano G, Pugliese G, Procaccini DA, Gesualdo L, Pellegrini F, Strippoli GF, LIRICO study group.
    J Nephrol; 2007 Jan 25; 20(6):646-55. PubMed ID: 18046666
    [Abstract] [Full Text] [Related]

  • 17. Albuminuria--a marker of renal and generalized vascular disease in insulin-dependent diabetes mellitus.
    Jensen T.
    Dan Med Bull; 1991 Apr 25; 38(2):134-44. PubMed ID: 2060321
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminuria or normoalbuminuria.
    Viberti G, Chaturvedi N.
    Kidney Int Suppl; 1997 Dec 25; 63():S32-5. PubMed ID: 9407417
    [Abstract] [Full Text] [Related]

  • 19. Slowing progression along the renal disease continuum.
    Kopyt NP.
    J Am Osteopath Assoc; 2005 Apr 25; 105(4):207-15. PubMed ID: 15928338
    [Abstract] [Full Text] [Related]

  • 20. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients.
    So WY, Ozaki R, Chan NN, Tong PC, Ho CS, Lam CW, Ko GT, Chow CC, Chan WB, Ma RC, Chan JC.
    Hypertension; 2004 Sep 25; 44(3):294-9. PubMed ID: 15249544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.